{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:42:11Z","timestamp":1790174531079,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd012349","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T00:00:00Z","timestamp":1525737600000}}],"reference-count":134,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012349.pub2","type":"journal-article","created":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T12:16:33Z","timestamp":1525781793000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia"],"prefix":"10.1002","volume":"2018","author":[{"given":"Patricia M","family":"Fortin","sequence":"first","affiliation":[{"name":"5639 Gowland Rd. Sechelt BC Canada V0N 3A8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila A","family":"Fisher","sequence":"additional","affiliation":[{"name":"NHS Blood and Transplant; Systematic Review Initiative; Level 2, John Radcliffe Hospital Headington Oxford Oxon UK OX3 9BQ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen V","family":"Madgwick","sequence":"additional","affiliation":[{"name":"North Middlesex University Hospital NHS Trust; Department of Pathology; Sterling Way London UK N18 1QX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marialena","family":"Trivella","sequence":"additional","affiliation":[{"name":"University of Oxford; Centre for Statistics in Medicine; Botnar Research Centre Windmill Road Oxford UK OX3 7LD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Hopewell","sequence":"additional","affiliation":[{"name":"University of Oxford; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS); Botnar Research Centre, Windmill Road Oxford Oxfordshire UK OX3 7LD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Doree","sequence":"additional","affiliation":[{"name":"NHS Blood and Transplant; Systematic Review Initiative; Level 2, John Radcliffe Hospital Headington Oxford Oxon UK OX3 9BQ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise J","family":"Estcourt","sequence":"additional","affiliation":[{"name":"NHS Blood and Transplant; Haematology\/Transfusion Medicine; Level 2, John Radcliffe Hospital Headington Oxford UK OX3 9BQ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,5,8]]},"reference":[{"issue":"11","key":"10.1002\/14651858.CD012349.pub2-BIB0001|cit1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.557.557","article-title":"A randomized controlled trial comparing the combination therapy of deferiprone (DFP) and desferrioxamine (DFO) versus DFP or DFO monotherapy in patients with thalassemia major","volume":"108","author":"Aydinok","year":"2006","journal-title":"Blood"},{"issue":"12","key":"10.1002\/14651858.CD012349.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3324\/haematol.11414","article-title":"A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major","volume":"92","author":"Aydinok","year":"2007","journal-title":"Haematologica"},{"issue":"S1","key":"10.1002\/14651858.CD012349.pub2-BIB0003|cit3","first-page":"190","article-title":"A randomized controlled prospective clinical study comparing the combination therapy of deferiprone (L1) and desferrioxamine with L1 and DFO monotherapy in patients with thalassemia major","volume":"91","author":"Manz","year":"2006","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0004|cit4","unstructured":"Badawy S Hassan TH Hesham MA Badr MA Evaluation of iron chelation therapy in B-thalassemic patients in Zagazig University Hospital ASPHO abstracts (The American Society of Pediatric Hematology\/Oncology) 2010 799 800"},{"issue":"4","key":"10.1002\/14651858.CD012349.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/bcpt.12695","article-title":"Clinical pharmacist-provided services in iron overloaded Beta-thalassemia major children; A new insight to patient care","volume":"120","author":"Bahnasawy","year":"2017","journal-title":"Basic & Clinical Pharmacology & Toxicology"},{"issue":"7","key":"10.1002\/14651858.CD012349.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/ajh.24024","article-title":"Deferiprone versus deferoxamine in thalassemia intermedia: results from a 5-year long-term Italian multicenter randomized clinical trial","volume":"90","author":"Calvaruso","year":"2015","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0007|cit7","doi-asserted-by":"crossref","unstructured":"Vitrano A Calvaruso G Di Maggio G Romeo MA Cianciulli P Lai ME Deferiprone versus deferoxamine in thalassemia intermedia: results from 5-year long-term Italian multi-center randomized clinical trial 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, California 2014","DOI":"10.1182\/blood.V124.21.1354.1354"},{"issue":"S1","key":"10.1002\/14651858.CD012349.pub2-BIB0008|cit8","first-page":"443","article-title":"18 months data of a randomized controlled trial of combined deferiprone (DFP) and deferasirox (DFX) versus combined deferiprone and deferoxamine (DFO), in young B-thalassemia major","volume":"99","author":"Elalfy","year":"2014","journal-title":"Haematologica"},{"issue":"5","key":"10.1002\/14651858.CD012349.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/ejh.12507","article-title":"Efficacy and safety of a novel combination of two oral chelators deferasirox\/deferiprone over deferoxamine\/deferiprone in severely iron overloaded young beta thalassemia major patients","volume":"95","author":"Elalfy","year":"2015","journal-title":"European Journal of Haematology"},{"issue":"21","key":"10.1002\/14651858.CD012349.pub2-BIB0010|cit10","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.559.559","article-title":"Comparison of two combination iron chelation regimens, deferiprone and deferasirox versus deferiprone and deferoxamine, in pediatric patients with beta-thalassemia major","volume":"122","author":"Elalfy","year":"2013","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0012|cit11","unstructured":"Study With Deferiprone and\/or Desferrioxamine in Iron Overloaded Patients ClinicalTrials.gov 2006"},{"issue":"7","key":"10.1002\/14651858.CD012349.pub2-BIB0011|cit12","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00277-008-0471-2","article-title":"Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience","volume":"87","author":"El-Beshlawy","year":"2008","journal-title":"Annals of Hematology"},{"issue":"11 Pt 1","key":"10.1002\/14651858.CD012349.pub2-BIB0013|cit13","article-title":"Safety and efficacy of alternate desferrioxamine and deferiprone compared to desferrioxamine alone in the treatment of iron overload in transfusion-dependent thalassemia patients","volume":"104","author":"Galanello","year":"2004","journal-title":"Blood"},{"issue":"10","key":"10.1002\/14651858.CD012349.pub2-BIB0014|cit14","first-page":"1343","article-title":"Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major","volume":"91","author":"Galanello","year":"2006","journal-title":"Haematologica"},{"issue":"5","key":"10.1002\/14651858.CD012349.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.19082\/2425","article-title":"Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: A comparative study of deferasirox and deferoxamine","volume":"8","author":"Hassan","year":"2016","journal-title":"Electronic physician"},{"issue":"11","key":"10.1002\/14651858.CD012349.pub2-BIB0016|cit16","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.575.575","article-title":"Deferiprone versus sequential deferiprone-deferoxamine treatment in thalassemia major: a five years multicenter randomized clinical trial under the auspices of the society for the study of thalassemia and hemogobinopathies (SoST)","volume":"110","author":"Maggio","year":"2007","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0017|cit17","first-page":"Abstract no: 38","article-title":"Decrease of mortality during deferiprone treatments: results from a large randomised cohort of thalassemia major patients under the auspices of the Italian society for thalassemia and hemogobinopathies","volume":"112 Suppl","author":"Maggio","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD012349.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2141.2009.07609.x","article-title":"Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: A randomized clinical trial","volume":"145","author":"Maggio","year":"2009","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0019|cit19","unstructured":"NCT00733811 Efficacy Study of the Use of Sequential DFP-DFO Versus DFP https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00733811"},{"issue":"3","key":"10.1002\/14651858.CD012349.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3109\/03630269.2011.570674","article-title":"Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: Main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients","volume":"35","author":"Pantalone","year":"2011","journal-title":"Hemoglobin"},{"issue":"1","key":"10.1002\/14651858.CD012349.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1046\/j.1365-2141.2003.04240.x","article-title":"Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients","volume":"121","author":"Mourad","year":"2003","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0022|cit22","unstructured":"Olivieri N the Iron Chelation Research Group Randomized trial of deferiprone (LI) and deferoxamine (DFO) in thalassemia major Blood 1996 651a"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0024|cit23","unstructured":"Olivieri NF Brittenham GM Evidence of progression of myocardial iron loading as determined by magnetic resonance imaging (MRI) in thalassemia patients during treatment with deferiprone (L1) and deferoxamine (DFO) Blood 1999 35b"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0025|cit24","unstructured":"Olivieri NF Brittenham GM Final results of the randomized trial of deferiprone (L1) and deferoxamine (DFO) Blood 1997 264a"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0023|cit25","unstructured":"Olivieri NF Brittenham GM Armstrong SAM Basran RK Daneman R Daneman N First prospective randomized trial of the iron chelators deferiprone (L1) and deferoxamine Blood 1995 249a"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0026|cit26","unstructured":"Pope Elena Critical review of standard and new methods of assessing compliance with chelation therapy in thalassemic patients Proquest Dissertations Publishing 1995"},{"issue":"9","key":"10.1002\/14651858.CD012349.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2005-07-2948","article-title":"Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis","volume":"107","author":"Pennell","year":"2006","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0028|cit28","doi-asserted-by":"crossref","unstructured":"Smith GC Alpendurada F Carpenter JP Alam MH Berdoukas V Kargiorga M Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload Journal of Cardiovascular Magnetic Resonance 2011 34","DOI":"10.1186\/1532-429X-13-34"},{"issue":"3","key":"10.1002\/14651858.CD012349.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/ejh.12487","article-title":"Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: results from the CORDELIA study","volume":"95","author":"Aydinok","year":"2015","journal-title":"European Journal of Haematology"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0030|cit30","first-page":"384","article-title":"Prevalence of cardiac iron overload in patients with transfusion-dependent anemias: data from the randomized, active-controlled deferasirox CORDELIA trial","volume":"97 Suppl 1","author":"Pennell","year":"2012","journal-title":"Haematologica"},{"issue":"21","key":"10.1002\/14651858.CD012349.pub2-BIB0031|cit31","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.2124.2124","article-title":"A multicenter, randomized, open-label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with beta-thalassemia major and iron overload (CORDELIA)","volume":"120","author":"Pennell","year":"2012","journal-title":"Blood"},{"issue":"10","key":"10.1002\/14651858.CD012349.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1182\/blood-2013-04-497842","article-title":"A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in beta-thalassemia major (CORDELIA)","volume":"123","author":"Pennell","year":"2014","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0033|cit33","unstructured":"A randomized, open-label, multicenter, two arm, phase II study to investigate the benefits of an improved deferasirox formulation (Film-coated Tablet) ClinicalTrials.go 2014"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0034|cit34","unstructured":"A randomized, open-label, multicenter, two arm, phase II study to investigate the benefits of an improved deferasirox formulation (film-coated tablet) EU Clinical Trials Register"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0035|cit35","doi-asserted-by":"crossref","unstructured":"Huang VW Banderas B Sen R Psychometric evaluation of clinical outcomes assessments in a phase II trial Value in Health 2016 A746","DOI":"10.1016\/j.jval.2016.09.2285"},{"issue":"5","key":"10.1002\/14651858.CD012349.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/ajh.24668","article-title":"New film-coated tablet formulaion of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, Phase II ECLIPSE study","volume":"92","author":"Taher","year":"2017","journal-title":"American Journal of Hematology"},{"issue":"11","key":"10.1002\/14651858.CD012349.pub2-BIB0037|cit37","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.1770.1770","article-title":"Improved endothelial function combined chelation therapy in thalassaemia major","volume":"108","author":"Tanner","year":"2006","journal-title":"Blood"},{"issue":"14","key":"10.1002\/14651858.CD012349.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1161\/CIRCULATIONAHA.106.648790","article-title":"A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance","volume":"115","author":"Tanner","year":"2007","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0039|cit39","unstructured":"Tanner MA Galanello R Dessi C Smith GC Westwood MA Agus A The effect of combined therapy with deferoxamine and deferiprone on myocardial iron and endothelial function in thalassaemia major: a randomized controlled trials using cardiovascular magnetic resonance Haematologica 2006 191"},{"issue":"11 Pt 1","key":"10.1002\/14651858.CD012349.pub2-BIB0040|cit40","article-title":"A randomized, placebo controlled, double blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassaemia major using cardiovascular magnetic resonance","volume":"106","author":"Tanner","year":"2005","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0051|cit41","unstructured":"Vichinsky E Patient reported outcomes with chelation therapy in patients with sickle cell disease (SCD) on either deferasirox (Exjade\u00ae, ICL670) or deferoxamine (DFO) 29th annual meeting of the National Sickle Cell Disease Program; April 8-12; Memphis, USA 2006"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0052|cit42","unstructured":"Vichinsky E Results of a randomized, controlled phase two trials of deferasirox (Exjade\u00ae, ICL670) in sickle cell disease patients with chronic overload 29th Annual Meeting of the National Sickle Cell Disease Program; April 8-12; Memphis, USA 2006"},{"issue":"3","key":"10.1002\/14651858.CD012349.pub2-BIB0041|cit43","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2141.2011.08720.x","article-title":"Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease","volume":"154","author":"Vichinsky","year":"2011","journal-title":"British Journal of Haematology"},{"issue":"21","key":"10.1002\/14651858.CD012349.pub2-BIB0042|cit44","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.845.845","article-title":"Long-term safety and efficacy of deferasirox (Exjade\u00ae) in transfused patients with sickle cell disease treated for up to 5 years","volume":"118","author":"Vichinsky","year":"2011","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0043|cit45","unstructured":"Vichinsky E Coates T Thompson A Bernaudin F Lagrone D Dong V Safety and efficacy of iron chelation therapy with deferasirox in patients with sickle cell disease (SCD): 3.5-year follow-up 14th Congress of the European Haematology Association; Jun 4-7; Berlin, Germany 2009"},{"issue":"11","key":"10.1002\/14651858.CD012349.pub2-BIB0044|cit46","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.1420.1420","article-title":"Deferasirox (Exjade\u00ae), the once-daily oral iron chelator, demonstrates safety and efficacy in patients with sickle cell disease (SCD): 3.5-year follow-up","volume":"112","author":"Vichinsky","year":"2008","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0045|cit47","doi-asserted-by":"crossref","unstructured":"Vichinsky E Coates T Thompson AA Bernaudin F Rodriguez M Rojkjaer L Deferasorix (Exjade\u00c2\u00ae), the once-daily oral iron chelator, demonstrates safety and efficacy in patients with sickle cell disease (SCD): 3.5-year follow-up 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; Feb 18-20; Florida, USA 2009","DOI":"10.1182\/blood.V112.11.1420.1420"},{"issue":"11 Pt 1","key":"10.1002\/14651858.CD012349.pub2-BIB0046|cit48","first-page":"995A","article-title":"Long-term efficacy and safety of deferasirox (Exjade\u00c2\u00ae, ICL670), a once-daily oral iron chelator, in patients with sickle cell disease (SCD)","volume":"110","author":"Vichinsky","year":"2007","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0047|cit49","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.313.313","article-title":"A randomized, controlled phase two trial in sickle cell disease patients with chronic iron overload demonstrates that the once-daily oral iron chelator deferasirox (Exjade\u00c2\u00ae, ICL670) is well tolerated and reduces iron burden","volume":"106","author":"Vichinsky","year":"2005","journal-title":"Blood"},{"issue":"11 Pt 1","key":"10.1002\/14651858.CD012349.pub2-BIB0048|cit50","article-title":"Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): Comparison between deferasirox (Exjade\u00c2\u00ae, ICL670) and deferoxamine (DFO)","volume":"106","author":"Vichinsky","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD012349.pub2-BIB0049|cit51","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-2141.2006.06455.x","article-title":"A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease","volume":"136","author":"Vichinsky","year":"2007","journal-title":"British Journal of Haematology"},{"issue":"3","key":"10.1002\/14651858.CD012349.pub2-BIB0050|cit52","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000125550","article-title":"Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial","volume":"119","author":"Vichinsky","year":"2008","journal-title":"Acta Haematologica"},{"issue":"5","key":"10.1002\/14651858.CD012349.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1179\/1607845414Y.0000000197","article-title":"Impact of educational programme regarding chelation therapy on the quality of life for B-thalassemia major children","volume":"20","author":"Abu","year":"2015","journal-title":"Hematology"},{"issue":"7","key":"10.1002\/14651858.CD012349.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3109\/08880018.2014.939792","article-title":"Predictors of non-adherence to follow-up visits and deferasirox chelation therapy among Jordanian adolescents with Thalassemia major","volume":"31","author":"Al-Kloub","year":"2014","journal-title":"Pediatric Hematology and Oncology"},{"issue":"3","key":"10.1002\/14651858.CD012349.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/ijn.12143","article-title":"Impact of psychosocial status and disease knowledge on deferoxamine adherence among thalassaemia major adolescents","volume":"20","author":"Al-Kloub","year":"2014","journal-title":"International Journal of Nursing Practice"},{"issue":"1","key":"10.1002\/14651858.CD012349.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2141.1995.tb05274.x","article-title":"Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators","volume":"91","author":"Al-Refaie","year":"1995","journal-title":"British Journal of Haematology"},{"issue":"10","key":"10.1002\/14651858.CD012349.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1097\/MPH.0b013e3181b53363","article-title":"Adherence to deferasirox in children and adolescents with sickle cell disease during 1-year of therapy","volume":"31","author":"Alvarez","year":"2009","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0058|cit58","doi-asserted-by":"crossref","unstructured":"Armstrong EP Skrepnek GH Ballas SK Kwok P Snodgrass S Sasane M Costs, persistence, and hospitalizations associated with the use of iron-chelating therapies in sickle cell disease in medicaid patients Blood 2011","DOI":"10.1182\/blood.V118.21.3152.3152"},{"issue":"2","key":"10.1002\/14651858.CD012349.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"151","DOI":"10.5958\/0974-9357.2014.00624.2","article-title":"Treatment adherence and quality of life of thalassemic children","volume":"6","author":"Bala","year":"2014","journal-title":"International Journal of Nursing Education"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1749-6632.1989.tb24191.x","article-title":"Health care adherence of persons with sickle cell disease. The role of social support","volume":"565","author":"Belgrave","year":"1989","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"3","key":"10.1002\/14651858.CD012349.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/j.1552-4604.1995.tb04062.x","article-title":"Use of a eutectic mixture of local anesthetics for prolonged subcutaneous drug administration","volume":"35","author":"Berkovitch","year":"1995","journal-title":"Journal of Clinical Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD012349.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4081\/thal.2013.e2","article-title":"Can the availability of unrestricted financial support improve the quality of care of thalassemics in a center with limited resources? A single center study from India","volume":"3","author":"Chakrabarti","year":"2013","journal-title":"Thalassemia Reports"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0063|cit63","unstructured":"Daar S Al Salmi F Ableen V Jacob W Jabeen Z Pathare A T2*MRI - An effective tool to increase chelation compliance in thalassemia major Haematologica 2010 698"},{"issue":"1","key":"10.1002\/14651858.CD012349.pub2-BIB0064|cit64","first-page":"21","article-title":"Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children","volume":"41","author":"Gomber","year":"2004","journal-title":"Indian Pediatrics"},{"issue":"4","key":"10.1002\/14651858.CD012349.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1365-2141.2008.07234.x","article-title":"Adherence to desferrioxamine and deferiprone and the impact of deferiprone co-prescription in thalassaemia major patients. Does the addition of deferiprone improve adherence?","volume":"142","author":"Kidson-Gerber","year":"2008","journal-title":"British Journal of Haematology"},{"issue":"1-2","key":"10.1002\/14651858.CD012349.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/03630260701727085","article-title":"Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine\/deferiprone combination. Identification of effective chelation therapy protocols","volume":"32","author":"Kolnagou","year":"2008","journal-title":"Hemoglobin"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0067|cit67","doi-asserted-by":"crossref","unstructured":"Leonard S Jonassaint J Anderson L Shah N The use of mobile technology for intensive training in medication management in the pediatric population Blood 2014","DOI":"10.1182\/blood.V124.21.4842.4842"},{"issue":"4","key":"10.1002\/14651858.CD012349.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/jpepsy\/jsv084","article-title":"Systematic and meta-analytic review: medication adherence among pediatric patients With sickle cell disease","volume":"41","author":"Loiselle","year":"2016","journal-title":"Journal of Pediatric Psychology"},{"issue":"5","key":"10.1002\/14651858.CD012349.pub2-BIB0069|cit69","first-page":"Online","article-title":"Emotional impact in beta-thalassaemia major children following cognitive-behavioural family therapy and quality of life of caregiving mothers","volume":"5","author":"Mazzone","year":"2009","journal-title":"Clinical Practice and Epidemiology in Mental Health"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0070|cit70","unstructured":"NCT01709032 Combination deferasirox and deferiprone for severe iron overload in thalassemia https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01709032"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0071|cit71","unstructured":"NCT01825512 Multicentre, randomised, open label, non-inferiority active-controlled trial to evaluate the efficacy and safety of deferiprone compared to deferasirox in paediatric patients aged from 1 month to less than 18 years of age affected by transfusion-dependent haemoglobinopathies https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01825512"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0072|cit72","unstructured":"NCT02133560 Use of mobile technology for intensive training in medication management https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02133560"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0073|cit73","unstructured":"NCT02466555 Music Therapy in Sickle Cell Transition Study https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02466555"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0074|cit74","doi-asserted-by":"crossref","unstructured":"Pakbaz Z Fischer R Gamino R Quirolo K Yamashita R Treadwell M Assessing compliance to iron chelation therapy in patients with thalassemia Blood 2004 33B","DOI":"10.1182\/blood.V104.11.3787.3787"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1196\/annals.1345.065","article-title":"A simple model to assess and improve adherence to iron chelation therapy with deferoxamine in patients with thalassemia","volume":"1054","author":"Pakbaz","year":"2005","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0076|cit76","doi-asserted-by":"crossref","unstructured":"Porter JB Athanasiou-Metaxa M Bowden DK Troncy J Habr D Domokos G Improved patient satisfaction, adherence and health-related quality of life with deferasirox (Exjade) in beta-thalassemia patients previously receiving other iron chelation therapies Blood 2009","DOI":"10.1182\/blood.V114.22.2486.2486"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0077|cit77","first-page":"641","article-title":"Health- related quality of life, treatment satisfaction, adherence and persistence in beta-thalassemia and myelodysplastic syndrome patients with iron overload receiving deferasirox: results from the epic clinical trial","volume":"297","author":"Porter","year":"2012","journal-title":"Anemia"},{"issue":"11 Pt 1","key":"10.1002\/14651858.CD012349.pub2-BIB0078|cit78","article-title":"Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): Comparison between deferasirox (Exjade\u00ae, ICL670) and deferoxamine (DFO)","volume":"106","author":"Vichinsky","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD012349.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000125550","article-title":"Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial","volume":"119","author":"Vichinsky","year":"2008","journal-title":"Acta Haematologica"},{"issue":"3","key":"10.1002\/14651858.CD012349.pub2-BIB0080|cit80","first-page":"297","article-title":"Comparison of deferiprone and deferrioxamine for the treatment of transfusional iron overload in children with beta thalassemia major","volume":"26","author":"Waheed","year":"2014","journal-title":"Journal of Ayub Medical College, Abbottabad: JAMC"},{"issue":"6","key":"10.1002\/14651858.CD012349.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1542\/peds.2014-0177","article-title":"Medication adherence among pediatric patients with sickle cell disease: a systematic review","volume":"134","author":"Walsh","year":"2014","journal-title":"Pediatrics"},{"issue":"1","key":"10.1002\/14651858.CD012349.pub2-BIB0082|cit82","first-page":"11","article-title":"Subcutaneous bolus injection of deferoxamine is an alternative method to subcutaneous continuous infusion","volume":"28","author":"Yarali","year":"2006","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0083|cit83","unstructured":"Antmen B Organ K Sasmaz I Berktas M Kilinc Y A cohort study to assess the contribution of patient compliance program on persistence to deferasirox in patients with chronic iron overload in turkey (ex-pat program) Haematologica\/the Hematology Journal 2013 713 4"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0084|cit84","unstructured":"NCT00004982 Combination iron chelation therapy https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00004982"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0085|cit85","unstructured":"Consorzio per le Valutazioni Biologiche e Farmacologiche Multicentre, randomised, open label, non-inferiority active-controlled trial to evaluate the efficacy and safety of deferiprone compared to deferasirox in paediatric patients aged from 1 month to less than 18 years of age affected by transfusion-dependent haemoglobinopathies https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2012-000353-31\/IT (EU Clinical Trials Register)"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0086|cit86","unstructured":"Amirmoezi F To assess compliance, efficacy and satisfaction with two different formulation of deferasirox in patients with transfusion-dependent beta-thalassemia http:\/\/en.irct.ir\/trial\/16826 (Iranian Registry of Clinical Trails)"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0087|cit87","unstructured":"Cnossen MH A randomized trial evaluaTing the Effects of group medical AppointMents on self-efficacy and adherence in Sickle Cell Disease (TEAM study). - TEAM study http:\/\/www.trialregister.nl\/trialreg\/admin\/rctview.asp?TC=4750 (Erasmus Medical Center, Sophia Children's Hospital)"},{"issue":"21","key":"10.1002\/14651858.CD012349.pub2-BIB0088|cit88","first-page":"6","article-title":"A randomized controlled trial studying the effectiveness of group medical appointments on self-efficacy and adherence in sickle cell disease (TEAM study): study protocol","volume":"16","author":"Madderom","year":"2016","journal-title":"BMC Hematology"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0089|cit89","unstructured":"NCT02173951 An algorithm to start iron chelation in minimally transfused young beta-thalassemia major patients https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02173951 ClinicalTrials.gov"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0090|cit90","unstructured":"NCT02435212 Study to evaluate treatment compliance, efficacy and safety of an improved deferasirox formulation (granules) in pediatric patients (2-<18 years old) with iron overload https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02435212"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1477-7525-4-73","article-title":"The impact of iron overload and its treatment on quality of life: results from a literature review","volume":"4","author":"Abetz","year":"2006","journal-title":"Health and Quality of Life Outcomes"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0092|cit92","unstructured":"American Pharmacists Association National Association of Chain Drug Stores Foundation Medication therapy management in community pharmacy practice: core elements of an MTM service (version 2.0) American Pharmacists Association 2008 24"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0093|cit93","unstructured":"All-Party Parliamentary Group on Sickle Cell and Thalassaemia (APPG) Sickle cell disease and thalassaemia: A health check http:\/\/ukts.org\/pdfs\/awareness\/appg.pdf"},{"issue":"6","key":"10.1002\/14651858.CD012349.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/bjh.12825","article-title":"Current approach to iron chelation in children","volume":"165","author":"Aydinok","year":"2014","journal-title":"British Journal of Haematology"},{"issue":"6","key":"10.1002\/14651858.CD012349.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.1365-2214.2004.00478.x","article-title":"A literature review to identify interventions to improve the use of medicines in children","volume":"30","author":"Costello","year":"2004","journal-title":"Child: Care, Health and Development"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0096|cit96","unstructured":"Veritas Health Innovation Covidence systematic review software 2017"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0097|cit97","unstructured":"Deeks JJ Higgins JPT Altman DG on behalf of the Cochrane Statistical Methods Group editor(s) Chapter 9: Analysing data and undertaking meta-analysis. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0098|cit98","unstructured":"Effective Practice Organisation of Care (EPOC) EPOC Resources for review authors http:\/\/epoc.cochrane.org\/epoc-specific-resources-review-authors"},{"issue":"8","key":"10.1002\/14651858.CD012349.pub2-BIB0099|cit99","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004450.pub3","article-title":"Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia","author":"Fisher","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1038\/515S1a","article-title":"Sickle-cell disease","volume":"515","author":"Gravitz","year":"2014","journal-title":"Nature"},{"issue":"6 S4","key":"10.1002\/14651858.CD012349.pub2-BIB0101|cit101","first-page":"S298","article-title":"Sickle cell disease in Africa. A neglected cause of early childhood mortality","volume":"41","author":"Grosse","year":"2011","journal-title":"American Journal of Preventive Medicine"},{"issue":"10","key":"10.1002\/14651858.CD012349.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/S0027-9684(15)31069-5","article-title":"A systematic review of barriers and interventions to improve appropriate use of therapies for sickle cell disease","volume":"10","author":"Haywood","year":"2009","journal-title":"Journal of the National Medical Association"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0103|cit103","unstructured":"Higgins JPT Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0104|cit104","unstructured":"Higgins JPT Deeks JJ editor(s) Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0105|cit105","unstructured":"Higgins JPT Altman DG Sterne JAC on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group editor(s) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0106|cit106","unstructured":"Higgins JPT Deeks JJ Altman DG on behalf of the Cochrane Statistical Methods Group editor (s) Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editor(s). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"6","key":"10.1002\/14651858.CD012349.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"480","DOI":"10.2471\/BLT.06.036673","article-title":"Global epidemiology of haemoglobin disorders and derived service indicators","volume":"86","author":"Modell","year":"2008","journal-title":"Bulletin of the World Health Organization"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0108|cit108","unstructured":"National Collaborating Centre for Mental Health Depression in adults with a chronic physical health problem: treatment and management. Clinical guideline [CG91] www.nice.org.uk\/guidance\/cg91"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0109|cit109","unstructured":"The National Collaborating Centre for Primary Care Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence. NICE Guideline CG76 https:\/\/www.nice.org.uk\/guidance\/cg76"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0110|cit110","unstructured":"National Institute for Health and Care Excellence Depression in adults with chronic physical health problem: recognition and management. NICE guideline CG91 www.nice.org.uk\/guidance\/cg91"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0111|cit111","unstructured":"NICE National Institute for health and Care Excellence Sickle cell disease http:\/\/cks.nice.org.uk\/sickle-celldisease#!backgroundsub:3"},{"issue":"8","key":"10.1002\/14651858.CD012349.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s12325-008-0085-z","article-title":"Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload","volume":"25","author":"Payne","year":"2008","journal-title":"Advances in Therapy"},{"issue":"9861","key":"10.1002\/14651858.CD012349.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(12)61229-X","article-title":"Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates","volume":"381","author":"Piel","year":"2012","journal-title":"Lancet"},{"issue":"20","key":"10.1002\/14651858.CD012349.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1056\/NEJMra1404415","article-title":"The \u03b1-thalassemias","volume":"371","author":"Piel","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/515S2a","article-title":"Epidemiology: a moving target","volume":"515","author":"Pleasants","year":"2014","journal-title":"Nature"},{"issue":"9757","key":"10.1002\/14651858.CD012349.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(10)61029-X","article-title":"Sickle-cell disease","volume":"376","author":"Rees","year":"2010","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0117|cit117","unstructured":"Reeves BC Deeks JJ Higgins JPT Wells GA on behalf of the Cochrane Non-Randomised Studies Methods Group Chapter 13: Including non-randomized studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0118|cit118","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"8","key":"10.1002\/14651858.CD012349.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s12325-010-0049-y","article-title":"An instrument assessing satisfaction with iron chelation therapy: Psychometric testing from an open-label clinical trial","volume":"27","author":"Rofail","year":"2010","journal-title":"Advances in Therapy"},{"issue":"11","key":"10.1002\/14651858.CD012349.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1056\/NEJMra050436","article-title":"\u03b2-Thalassemia","volume":"353","author":"Rund","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012349.pub2-BIB0121|cit121","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007768.pub3","article-title":"Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews","author":"Ryan","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0122|cit122","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Guyatt GH on behalf of the Cochrane Applicability and Recommendations Methods Group and the Cochrane Statistical Methods Group Chapter 11: Presenting results and \u2018Summary of findings\u2019 tables. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0123|cit123","unstructured":"Sterne JAC Egger M Moher D on behalf of the Cochrane Bias Methods Group editor(s) Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0124|cit124","unstructured":"Sterne JAC Higgins JPT Reeves BC on behalf of the development group for ROBINS-I ROBINS-I: a tool for assessing Risk Of Bias In Non-randomized Studies of Interventions, Version 7 March 2016 www.riskofbias.info"},{"issue":"9","key":"10.1002\/14651858.CD012349.pub2-BIB0125|cit125","first-page":"1187","article-title":"Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004","volume":"91","author":"Telfer","year":"2006","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"41","DOI":"10.53841\/bpscpf.2013.1.246.41","article-title":"Implementing the NICE clinical guideline 91 ('Depression in adults with a chronic physical health problem') in a haematology department","volume":"246","author":"Thomas","year":"2013","journal-title":"Clinical Psychology Forum"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/1477-7525-10-148","article-title":"Beliefs about chelation among thalassemia patients","volume":"10","author":"Trachtenberg","year":"2012","journal-title":"Health and Quality of Life Outcomes"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1007\/s11136-014-0671-2","article-title":"Relationship among chelator adherence, change in chelators, and quality of life in Thalassemia","volume":"23","author":"Trachtenberg","year":"2014","journal-title":"Quality of Life Research"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0129|cit129","unstructured":"United Kingdom Thalassaemia Society Standards for the clinical care of children and adults with thalassaemia in the UK UK Thalassaemia Society 2008 120"},{"issue":"3","key":"10.1002\/14651858.CD012349.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3111\/13696998.2015.1117979","article-title":"Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia","volume":"19","author":"Vekeman","year":"2016","journal-title":"Journal of Medical Economics"},{"issue":"3","key":"10.1002\/14651858.CD012349.pub2-BIB0131|cit131","first-page":"254","article-title":"Medication compliance research","volume":"3","author":"Wertheimer","year":"2003","journal-title":"Journal of Applied Research in Clinical and Experimental Therapeutics"},{"key":"10.1002\/14651858.CD012349.pub2-BIB0132|cit132","unstructured":"World Health Organization Adherence to long-term therapies: Evidence for action WHO 2003 194"},{"issue":"10","key":"10.1002\/14651858.CD012349.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jama.2014.10517","article-title":"Management of sickle cell disease:summary of the 2014 evidence-based report by expert panel members","volume":"312","author":"Yawn","year":"2014","journal-title":"JAMA"},{"issue":"9","key":"10.1002\/14651858.CD012349.pub2-BIB0134|cit134","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012349","article-title":"Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia","author":"Fortin","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd012349.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T00:00:00Z","timestamp":1678060800000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD012349.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T13:59:32Z","timestamp":1693663172000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012349.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,5,8]]},"references-count":134,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012349.pub2","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD012349.pub3","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,8]]}}}